A total of four clinical trials focused on PF4, two of which were medical diagnostic devices and two of which were drugs, in patients with HIT, thrombosis, coronary artery bypass graft surgery presence of heparin/PF4 antibody, and end-stage renal disease. The gene discussed is PF4; the disease is stage 5 chronic kidney disease.